Skip to main content

Contraception clinical trials at UCSF
4 in progress, 3 open to new patients

  • Study Comparing Emergency Contraception Effectiveness in Women Who Weight ≥ 80 kg

    open to eligible females ages 18-40

    The proposed research study is a Phase IIb, multi-center, single-blind, randomized study of UPA 30 mg, LNG 1.5 mg and LNG 3.0 mg to evaluate EC effectiveness in women with weight ≥ 80 kg who present within 72 hours of unprotected intercourse.

    San Francisco, California and other locations

  • The Share Health Study: Teen Social Connections and Health

    open to eligible females ages 15-19

    The purpose of this study is to determine whether delivery of SpeakOut, a behavioral intervention to increase social communication about long-acting reversible contraceptive (LARC) methods among adolescents, is associated with increased uptake of LARC methods among the social contacts of SpeakOut recipients. The investigators will conduct a cluster randomized controlled trial of SpeakOut with adolescent LARC users and their female peers. Over three years, SpeakOut will be implemented in eight partner clinics. IUD and implant users aged 15 to 19 who attend appointments at participating clinics will be invited to enroll in the evaluation study as "primary" participants and receive either SpeakOut or a control intervention about alcohol use. The social contacts of primary participants will be asked to enroll in the study as "secondary" participants. The study's primary outcome will be the proportion of sexually-active secondary participants who initiate use of a LARC method within 9 months of study enrollment.

    Davis, California and other locations

  • UCSF College Health Study on Contraceptive Training and Education at Community Colleges

    open to eligible females ages 18-25

    The purpose of this study is to measure whether a training and education intervention for clinic staff and young women aged 18-25 on contraceptive methods, including intrauterine devices (IUDs) and the implant, will result in greater contraceptive knowledge and access among students in community colleges.

    San Francisco, California

  • Study of the Safety and Efficacy of Ulipristal Acetate (UPA) Used Daily as a Contraceptive

    Sorry, not yet accepting patients

    This is a Phase IIb multicenter, open-label, non-comparative trial of continuous daily oral 10 mg of ulipristal acetate (UPA) to evaluate its contraceptive efficacy as the primary method of contraception.

    San Francisco, California and other locations

Last updated: